Advanced Accelerator Applications, a Saint Genis Pouilly, France-based specialist in Molecular Nuclear Medicine (MNM), raised €41m in funding.
The round was led by biotech and pharma investment company HBM Healthcare Investments Ltd (€20m), with participation from existing and new shareholders, including Tamburi Investment Partners Group.
The company intends to use the funds for expansion and clinical trials of its portfolio of MNM diagnostic and therapeutic products.
Founded in 2002 and led by Stefano Buono, Chief Executive Officer, Advanced Accelerator Applications develops and commercializes diagnostic and therapeutic products including PET (Positron Emission Tomography) and SPECT (Single Photon Emission Computed Tomography) solutions. The company’s main focus is on molecular imaging and personalized medicines for the treatment of diseases such as cancer. It has 17 production and R&D facilities in Europe, Israel and North America and over 270 employees in 10 countries (France, Italy, Germany, Switzerland, Spain, Poland, Portugal, Israel, U.S., Canada).
In 2013, Advanced Accelerator Applications is expecting to reach revenues of €56.6m (+27% vs. 2012) and EBITDA of €14m (+49% vs. 2012).